2015;131:34 42. 168. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781 91. 169. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 81. 170. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456 67. 171. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015;373:2314 24. 172. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiester- ase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268 77. 173. Anker SD, Comin CJ, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436 48. 174. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in pa- tients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657 68. 175. Kapoor M, Schleinitz MD, Gemignani A, et al. Outcomes of patients with chronic heart failure and iron deficiency treated with intrave- nous iron: a meta-analysis. Cardiovasc Hematol Disord. Drug Targets. 2013;13:35 44. 176. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbe- poetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210 19. 177. Cleland JG, Sullivan JT, Ball S, et al. 